lipoxin a4 has been researched along with 14,15-epoxy-5,8,11-eicosatrienoic acid in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Croze, R; Levy, BD; Pfeffer, MA; Planagumà, A; Rubin, G; Serhan, CN; Uddin, M | 1 |
Bahl, CD; Bomberger, JM; Eddens, T; Flitter, BA; Hammock, BD; Hampton, TH; Hvorecny, KL; Kolls, JK; Kwak, DH; Lee, JS; Levy, BD; Liu, X; Madden, DR; Morisseau, C; Ono, E; Yang, J | 1 |
2 other study(ies) available for lipoxin a4 and 14,15-epoxy-5,8,11-eicosatrienoic acid
Article | Year |
---|---|
Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4.
Topics: 8,11,14-Eicosatrienoic Acid; Acute Disease; Animals; Anticholesteremic Agents; Cell Line; Disease Models, Animal; Female; Humans; Hypercholesterolemia; Inflammation; Inflammation Mediators; Lipoxins; Lovastatin; Male; Mice; Neutrophils; Pneumonia; Respiratory Mucosa | 2010 |
Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.
Topics: 8,11,14-Eicosatrienoic Acid; Bacterial Proteins; Bronchoalveolar Lavage Fluid; Cell Line; Crystallography, X-Ray; Cystic Fibrosis; Humans; Inflammation; Lipoxins; Lung Diseases; Neutrophil Activation; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Virulence Factors | 2017 |